2019
DOI: 10.1056/nejmoa1903822
|View full text |Cite
|
Sign up to set email alerts
|

Liraglutide in Children and Adolescents with Type 2 Diabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

13
243
0
11

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 263 publications
(267 citation statements)
references
References 15 publications
13
243
0
11
Order By: Relevance
“…In this context, it is noteworthy that reduction in BMI‐SDS and BMI was increasing throughout the study period and may be even more pronounced if the treatment duration was extended beyond the 6‐month period in the current study. Of note, this is in line with a recent study, in which adolescents with obesity and T2DM were randomly assigned to receive the GLP‐1 RA liraglutide or placebo for a 26‐week double‐blind period, followed by a 26‐week open‐label extension period, and showed that a reduction in BMI was not significant after 6, but 12 months …”
Section: Discussionsupporting
confidence: 86%
“…In this context, it is noteworthy that reduction in BMI‐SDS and BMI was increasing throughout the study period and may be even more pronounced if the treatment duration was extended beyond the 6‐month period in the current study. Of note, this is in line with a recent study, in which adolescents with obesity and T2DM were randomly assigned to receive the GLP‐1 RA liraglutide or placebo for a 26‐week double‐blind period, followed by a 26‐week open‐label extension period, and showed that a reduction in BMI was not significant after 6, but 12 months …”
Section: Discussionsupporting
confidence: 86%
“…Liraglutide is currently the only GLP‐1 RA approved in paediatric patients following results from the ellipse trial, but use is QD 14,72 . Incidence of GI AEs in the ellipse trial was as expected for this drug class, and a higher proportion of patients experienced serious AEs and hypoglycaemic episodes vs placebo 72 . There is a trial underway with QW exenatide ER in paediatric patients with T2D 73…”
Section: Resultsmentioning
confidence: 88%
“…A recent randomized clinical trial in children aged 10-17 years with type 2 diabetes demonstrated the addition of subcutaneous liraglutide (up to 1.8 mg daily) to metformin (with or without basal insulin) as safe and effective to decrease A1C (estimated decrease of 1.06 percentage points at 26 weeks and 1.30 at 52 weeks), although it did increase the frequency of gastrointestinal side effects (191). In June 2019, the U.S. Food and Drug Administration approved liraglutide injection for treatment of pediatric patients aged 10 years or older with type 2 diabetes (192).…”
Section: Management Of Cardiovascular Risk Factorsmentioning
confidence: 99%